Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease

March 18, 2026 updated by: Acibadem University

Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire in Individuals With Parkinson's Disease

This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.

Description

Inclusion Criteria:

  • Clinically diagnosed with Parkinson's disease

Aged between 40 and 85 years

MMSE score ≥ 24 (adequate cognitive level for communication)

Voluntary participation with informed consent

Patients attending the Movement Disorders Outpatient Clinic, Department of Neurology

Exclusion Criteria:

  • Presence of psychiatric disorders (major depression, psychotic disorders)

Diagnosis of advanced dementia

Severe visual or hearing impairment that may interfere with assessments

Inability to cooperate with the physiotherapist or complete the assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)
Time Frame: Baseline and 14-21 days for test-retest assessment
Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.
Baseline and 14-21 days for test-retest assessment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-Efficacy for Managing Chronic Disease (6-Item Scale)
Time Frame: Baseline
Assessment of perceived self-efficacy in managing chronic disease using the 6-Item Self-Efficacy for Managing Chronic Disease Scale. The scale evaluates individuals' confidence in managing symptoms such as pain, fatigue, emotional distress, and disease-related problems. It consists of 6 items scored on a 10-point Likert scale (1 = not at all confident, 10 = totally confident), with the total score calculated as the mean of all items. Higher scores indicate greater self-efficacy in disease management. The validated Turkish version will be used.
Baseline
Montreal Cognitive Assessment (MoCA-TR)
Time Frame: Baseline
Cognitive function will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR). This screening tool evaluates multiple cognitive domains including visuospatial/executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The validated Turkish version for Parkinson's disease will be used.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Acibadem University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

April 1, 2027

Study Registration Dates

First Submitted

March 18, 2026

First Submitted That Met QC Criteria

March 18, 2026

First Posted (Actual)

March 23, 2026

Study Record Updates

Last Update Posted (Actual)

March 23, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-05-223

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Cognitive Self-Efficacy Questionnaire (Turkish Version)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe